US 9096609
Macrocyclic LRRK2 kinase inhibitors
granted A61KA61K31/519A61P
Quick answer
US patent 9096609 (Macrocyclic LRRK2 kinase inhibitors) held by Oncodesign SA expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Oncodesign SA
- Grant date
- Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/519, A61P, A61P25/16, A61P25/28